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1027Letters to the EditorA Vision of
Future Treatment in
Chagas Heart DiseaseWe read the state-of-the-art paper byNunes et al. (1), which presents
the current knowledge on Chagas disease. For counteracting Chagas
heart disease, the most life-threatening complication in chronic
Chagas patients, the authors stated that “.management.
followed. recommendations for. heart failure due to other con-
ditions” (1), which includes the prevention of thromboembolism,
arrhythmia, dysautonomia, and ventricular dysfunction.
As mentioned by the authors, there are agonistic autoantibodies
against G-protein coupled receptors (GPCR-AABs), such as those
against the muscarinergic-2 receptor (M2-AABs) and the beta1-a-
drenergic receptor (beta1-AABs), which are found in nearly all Cha-
gas heart patients. M2-AABs are thought to contribute to patients’
dysautonomia, whereas beta1-AABs are seen as drivers of cardiomy-
opathy. Consequently, to counteract the pathogenic potency of
beta1-AABs, but presently only directed to beta1-AAB–positive pa-
tients with idiopathic dilated cardiomyopathy, new treatment strate-
gies are under study that focus on beta1-AAB removal via an apheresis
technique or drug treatment for in vivo beta1-AAB neutralization (2).
However, both strategies could also be helpful for Chagas patients.
In beta1-AAB apheresis technology, aptamers, a new class of
binders (in addition to peptides and proteins, the typical binders)
and speciﬁcally, the recently identiﬁed beta1-AAB-binding aptamer,
which was successfully tested in apheresis in animals (3), could be
introduced. Due to the dual presence of beta1- and M2-AABs
in Chagas heart patients, apheresis techniques that remove both
GPCR-AABs in parallel, either by whole immunoglobulin G
apheresis or using a column carrying our recently patented aptamer
(4), which binds to the majority of cardiotropic GPCR-AABs,
among which are M2- and beta1-AABs, should be optimal. How-
ever, the high costs and logistic problems of apheresis limit its
application for the millions of Chagas heart patients. To overcome
this, a treatment strategy using in vivo neutralization of GPCR-
AABs would be, in view of costs and logistics, optimal. In view of
“.excellent characteristics for systemic.administration appli-
cation.” (5) of aptamers in general and combined with the evi-
denced neutralizing function of our GPCR-AAB-binding aptamer
(4), we suggest that this molecule could be suitable for developing
an innovative therapy for patients with Chagas heart disease.Gerd Wallukat, PhD
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237–57.ReplyA Vision of Future Treatment
in Chagas Heart DiseaseWe would like to thank Dr. Wallukat and colleagues for their letter
regarding our review on Chagas heart disease (CHD) (1), which
suggested the potential value of new treatment strategies that focus
on removal or neutralization of beta1-autoantibodies (AABs). We
agree that this is an appealing possibility, but we consider the role
of beta1-AABs in the pathogenesis of Chagas cardiomyopathy
(ChCM) to still be controversial. There are a number of studies
showing a potential role of beta1-AABs in the genesis of major
clinical manifestations of ChCM, such as ventricular dysfunction,
ventricular arrhythmias, and conduction disturbances (reviewed in
Medei et al. [2]), most of them in vitro or in experimental models.
However, as observed for antimuscarinic AABs (3), some of the
properties of beta1-AABs observed in vitro or in experimental
models may not produce effects in clinical patients, due to the
concomitant action of other factors. A major ﬁnding favoring a
pathogenetic role of beta1-AABs in ChCM was published by
Wallukat et al. (4), who showed a higher prevalence of
chronotropically active beta1-AABs in CHD with cardiomyopathy
than in those in the indeterminate form or with megacolon, as well
as a higher activity of those AABs in ChCM patients.
However, much more data is necessary before a speciﬁc therapy
aimed to neutralize or remove beta1-AABs in CHD could be used
in clinical practice. Available clinical data does not show a dose-
response effect (i.e., that patients with more severe ChCM have
higher levels or activity of antiB1-AABs [4,5]). Longitudinal data
that consistently shows that higher AAB activity may provoke or
aggravate heart involvement in CHD would be desirable to further
conﬁrm the importance of the proposed mechanism. It is
conceivable that the pathogenesis of ChCM is multifactorial, as
discussed in our review (1). Finally, a formal proof-of-concept
clinical trial is needed to determine if this novel approach is safe
and effective in CHD. Because CHD is a neglected disease that
kills thousands of persons each year, novel and innovative therapies
should urgently be tested and are welcomed.
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Treat Sustained Ventricular
Tachycardia in Patients
With Chagas Cardiomyopathy
and Implantable
Cardioverter-DeﬁbrillatorWe have read with great interest the recent paper by Nunes et al.
(1). We congratulate the authors for this comprehensive review of
Chagas cardiomyopathy, which is one of the most important car-
diovascular problems in Latin America and also an emerging dis-
ease in nonendemic countries.
As the authors properly described, ventricular arrhythmias are
very common in patients with Chagas heart disease, with preva-
lence and complexity related to the presence and extent of
myocardial damage. Sustained rapid ventricular tachycardia (VT) isrecognized as the most important cause of sudden cardiac death in
Chagas disease. It has been identiﬁed in patients with a segmental
disease, with or without important ventricular dysfunction,
and the implantable cardioverter-deﬁbrillator (ICD) has been rec-
ommended for those patients to prevent sudden cardiac death.
However, some observations suggest that patients with Chagas
disease receive more ICD shocks when compared with patients
with other structural heart diseases (2,3). As previously shown (4),
frequent ICD shocks are associated with higher mortality in pa-
tients with low ejection fraction of any etiology. So, it is not sur-
prising that a similar observation applies to patients with Chagas
VT and frequent ICD discharges that have shown a high total
mortality rate when their deﬁbrillators are conventionally pro-
grammed (5,6).
It is important to mention that catheter ablation is currently
recommended to manage patients with incessant or recurrent
VTs, mainly when receiving frequent ICD therapies (7). In
treating hundreds of patients with these characteristics, we were
able to deﬁne the substrate of most of these VTs: most re-entrant
circuits in Chagas VTs originate in the inferior or lateral basal
wall of the left ventricle. Moreover, after developing the tech-
nique of subxiphoid percutaneous access to the pericardial space
in our laboratory, we were able to identify that subepicardial
myocardial ﬁbers were the cause for re-entrant circuits of sus-
tained VT in many patients with Chagas disease (8,9). This
ﬁnding has allowed us to successfully ablate VT for patients with
prior endocardial ablation failures (10). These observations have
been largely conﬁrmed in the literature, and are currently rec-
ommended for managing speciﬁc patients with recurrent VTs,
particularly those with Chagas VT and other nonischemic car-
diomyopathies (11,12).
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